SAN DIEGO, April 05, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty
pharmaceutical company developing therapeutics for the aesthetic market today announced the issuance of U.S. Patent Number
9,597,531 by the United States Patent and Trademark Office (USPTO). This patent is directed to specific methods of using
LIPO-202 and other agents for the reduction of fat accumulation. The ’531 patent is expected to expire no earlier than the fourth
quarter of 2031, extending the coverage time of the company’s intellectual property portfolio. This is the eighth issued U.S.
patent directed to Neothetics' lead product candidate LIPO-202, which is being evaluated for the reduction of submental
fat.
"This patent further strengthens our comprehensive intellectual property portfolio protecting our lead clinical asset,
LIPO-202,” said Martha J. Demski, a member of Neothetics’ Operating Committee and Board of Directors.
To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's
website at investors.neothetics.com and register for email alerts.
About LIPO-202
LIPO-202 is a proprietary, first-in-class injectable formulation of the well-known long-acting ß2-adrenergic receptor
agonist, salmeterol xinafoate, which is an active ingredient of FDA-approved inhaled products such as SEREVENT DISKUS®, ADVAIR HFA®
and ADVAIR DISKUS®. Our studies suggest that salmeterol xinafoate activates ß2 -adrenergic receptors on fat cells, triggering the
body’s natural process of metabolizing stored triglycerides (fat) resulting in a reduction in size and volume of the fat cells in
the treatment area without damage of nearby tissues. LIPO-202 has an extremely favorable safety profile, with little to no adverse
post treatment effects. LIPO-202 is being evaluated for the reduction of submental fat commonly referred to as a
double-chin.
About Neothetics, Inc.
Neothetics is a San Diego based clinical-stage specialty pharmaceutical company developing therapeutics for the
aesthetic market. Our initial focus is on localized fat reduction and body contouring. Our lead product candidate, LIPO-202, is a
first-in-class injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate, which is an active
ingredient in the U.S. Food and Drug Administration, or FDA, approved inhaled products SEREVENT DISKUS®, ADVAIR HFA® and ADVAIR
DISKUS®. For more information on Neothetics, please visit www.neothetics.com. Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or
registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements
regarding the ability to develop a modified formulation of LIPO-202, timing of conducting and obtaining results from Phase 2
trials and proof of concept study with a modified formulation of LIPO-202, whether our modified formulation of LIPO-202 is able to
demonstrate positive results, Neothetics’ plans to research, develop and commercialize LIPO-202 and other product candidates,
our expectations regarding the potential market size and opportunity of LIPO-202, as well as expected timing for reporting results
from clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. These forward-looking statements are based
upon Neothetics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with clinical
trials, such as the ability to timely initiate clinical trials and enroll a sufficient number of patients on a timely basis into
clinical trials, the extent to which top-line data is available and whether the clinical trials achieve positive results, product
development activities, obtaining regulatory approval to commercialize LIPO-202 and other product candidates, Neothetics’ use of
cash, and the need to raise additional funding, when needed, in order to conduct our clinical trials and other business, the
degree of market acceptance of LIPO-202 by physicians, patients and others in the medical community, our reliance on third parties,
including third-party suppliers for manufacturing and distribution of products, regulatory developments in the United States and
foreign countries, Neothetics’ ability to obtain and maintain intellectual property protection for LIPO-202 and its product
candidates, competition in the aesthetics industry and other market conditions. All forward-looking statements contained in this
press release speak only as of the date on which they were made. Neothetics undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist after the date on which they were made. Investors should
consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and
other documents the company files with the SEC available at www.sec.gov, including without limitation, Neothetics’ Form 10-K for the year ended December 31,
2016 and subsequent Quarterly Reports on Form 10-Q.
COMPANY CONTACTS: Susan A. Knudson Chief Financial Officer 858-500-7780 sknudson@neothetics.com Fara Berkowitz, R.Ph, Pharm.D Senior Director, Investor Relations and Corporate Development 646-494-1589 fberkowitz@neothetics.com
